

TRISTEL plc
("Tristel" or the "Company")

**Positive H1 Trading Update
& Directorate Change**

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces a positive trading update for the six months ended 31 December 2025. The board remains confident in delivering full year results in line with market expectations and the Company's own performance targets.

H1 Financial Highlights

- H1 revenues increased by 14% year-on-year
- Gross Margins maintained at 81%
- Adjusted EBITDA increased by 17%
- EBITDA margins of 28%, comfortably ahead of the 'at least 25% target'
- Continued progress in US with revenue growth in line with internal forecasts
- Tristel continues to be debt free and cash generative
- Cash balances at 31 December 2025 were £13.3m

The above highlights are based on unaudited figures and the Company intends to announce its interim results in early March.

Directorate Change

The Company also announces that Matt Sassone, Chief Executive Officer, has confirmed to the Board his decision to resign to take up a worldwide President role with a large US multinational, leading a significant global business. Matt will actively continue in post until the end of the financial year and has fully committed to continue leading the business through this period. The Board has already commenced the process to appoint a new CEO and is confident that there is sufficient management depth in the business to ensure that trading will not be impacted during the transition.

Commenting Matt Sassone, Chief Executive Officer, said:

"This is undoubtedly one of the hardest business decisions I have ever had to make. The real strength of Tristel has never been one person, as the business has been carefully built on leaders at every level. Our strategy for growth is robust and remains unchanged, and the momentum we have is very real and can be seen already in the strong H1 performance. I am confident that the investment case of the business remains as compelling as ever.

"The opportunity I have to return to the US with my family, and to work in such a senior role with a large US multinational, is one which resonates with me on a personal level. It is with a very heavy heart that I will be leaving Tristel and I remain confident in our ability to take full advantage of the market opportunities, particularly in the US where there is clear evidence of traction and scale-up potential.

"I would like to thank the Board and the wider Tristel team for their support and hard work, and I would like to reassure investors that the business remains in a very strong position. Any new CEO coming into this role will see that this business has a well established platform to deliver significant growth."

Bruno Holthof, Chair of the Tristel Board, commented: *"On behalf of the Company I would like to offer my thanks to Matt for his leadership, energy and contribution to Tristel since joining us in 2024. He has made a real impact in short period of time, and whilst we're sad to see him go, we respect his decision and wish him every success. We are confident in the strength of the leadership team and the wider organisation, and we remain confident that the strong momentum of the business will continue. The Board has already commenced the process of recruiting a new CEO, working carefully to find the right leader to build on the strong foundations already in place."*

For further information please contact:

Tristel plc

Matt Sassone, Chief Executive Officer
Anna Wasyl, Chief Financial Officer

Via Walbrook PR
<https://investors.tristel.com/>

Walbrook PR Ltd

Paul McManus / Lianne Applegarth / Anna Dunphy

Tel: 020 7933 8780 or tristel@walbrookpr.com
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

Cavendish Capital Markets Ltd

Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (ECM) / Louise Talbot (Sales)

Tel: 020 7220 0500



About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the **Tristel** brand, and under the **Cache** brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPPUWWGUPQGMG